Pacific Edge Limited · NZX:PEB
Pacific Edge — H1 2019 Earnings Presentation
16 slides from Pacific Edge's earnings presentation, Nov 29, 2018
Slide 1: FY19 Interim Result and Capital Raise Presentation
FY19 INTERIM RESULT AND CAPITAL RAISE PRESENTATION 29 November 2018
Slide 2: Cxbladder: Better Solutions, Better Care
CXBLADDER BETTER SOLUTIONS BETTER CARE Our goals are to enable better patient care, better clinical decision making and better use of healthcare resources by providing faster, more accurate and less invasive diagnosis and management of bladder cancer Pacific Edge FY19 Half Year Result and Capital Ra
Slide 3: Haematuria and Bladder Cancer
HAEMATURIA AND BLADDER CANCER The US opportunity dominates our commercial focus Approx. 7 million 70% recurrence rate people present with 16 years of R&D and leads to many clinical haematuria annually procedures validation Pacific Edge’s in the USA addressable market in the USA alone has been Highes
Slide 4: Cxbladder
CXBLADDER Validated by world leading physicians The first new diagnostic tests for bladder cancer to be made commercially available in the US market in 16 years, disrupting clinical pathways and standards of care. Four high performance Cxbladder products in use by clinicians and now being integrated
Slide 5: Capital Raising
CAPITAL RAISING • Pacific Edge intends to undertake a placement of Placement Timetable new shares at $0.35 to raise up to $7m Pacific Edge in trading halt 29 November • The placement bookbuild will occur on the 29th of November with participants including a range Placement undertaken 29 November of
Slide 6: 1H19 Highlights and Milestones
1H19 HIGHLIGHTS AND MILESTONES INCREASED TEST SALES Up 43% on prior comparative first half year period (pcp). INCREASE IN BILLABLE TESTS Up 12%, relative to a strong pcp. Currently account for 82% of total laboratory throughput and continues to increase. IMPROVEMENT IN NET Net operating cash o
Slide 7: Cxbladder replaces cystoscopy in standard of care
Cxbladder replaces cystoscopy in standard of care New Zealand’s public healthcare providers are leading the global adoption of Cxbladder 62% (1H19) coverage up from 36% (1H18) Pacific Edge FY19 Half Year Result and Capital Raise Presentation Slide 7
Slide 8: 1H19 Results Snapshot
1H19 RESULTS SNAPSHOT HIGHLIGHTS: 1H19 1H18 1H18: 1H19 (NZ$’000) (unaudited) (unaudited) (% change) • 43% increase in test sales Operating Revenue1 (test sales) 2,033 1,425 43% • 6% decrease in operating expenses Other Revenue 606 627 (3%) • Operating cash outflow reduced 15% Total Revenue 2,639 2,0
Slide 9: Key Metrics: Laboratory Throughput
KEY METRICS: LABORATORY THROUGHPUT • 12% increase in billable test volumes, consolidating and LABORATORY THROUGHPUT (Commercial tests and User Programmes) growing on the strong numbers in 1H18 82% of 1H19 tests are billable • Billable tests account for 82% of total volume (1H18 76%) 14.0 • CMS tests
Slide 10: Key Metrics: Operating Cashflow
KEY METRICS: OPERATING CASHFLOW • Net operating cash outflow reduced to ($8.6m), a 15% decrease on 1H18: ($10.2m) Operating cash outflow reduced 16% • Monthly cash outflow for 1H19 reduced to average $1.4m (1H18: $1.7m). The first half of the financial year traditionally 1H19 1H18 1H18: 1H19 (NZ$’00
Slide 11: Focus for 2H19
FOCUS FOR 2H19 Commercial growth in USA remains a focus for the Board and Management Focus on growing the number of large institutional healthcare accounts including Kaiser Permanente and the remaining public healthcare providers in NZ Attain inclusion in LCD for CMS patients, which make up ap
Slide 12: Comparative Commercial Laboratory Test Throughput
COMPARATIVE COMMERICAL LABORATORY TEST THROUGHPUT Half Year comparison FY17-FY19 (Number of Tests) 1H17 2H17 FY17 1H18 2H18 FY18 1H19 2H19e FY19e Total Laboratory Throughput1 5,622 5,624 11,246 7,119 7,329 14,448 7,397 9,103 16,5001 Billable Tests 4,112 4,185 8,297 5,439 6,427 11,866 6,078 7,464 13,
Slide 13: Outlook
OUTLOOK COMMERCIAL PERFORMANCE: Stronger second half LABORATORY THROUGHPUT expected in line with annual trends, with uplift in year on (Commercial tests and User Programmes) year revenue FY19 laboratory throughput CASHFLOW: Continued improvement in operating estimate of 16,5001 tests cashflow ex
Slide 14: Contact
David Darling CONTACT: Chief Executive Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 www.pacificedge.co.nz www.cxbladder.com Email: david.darling@pelnz.com www.pacificedgedx.com
Slide 15: Disclaimer
DISCLAIMER Important Notice This presentation has been prepared by Pacific Edge Limited (PEL) solely to provide interested parties with further information about PEL and its activities at the date of this presentation. Information of a general nature The information in this presentation is of a gene
Slide 16: Disclaimer
DISCLAIMER Past performance Investors should note that past performance, including past share price performance, cannot be relied upon as an indicator of (and provides no guidance as to) future PEL performance, including future financial position or share price performance. Investment risk An invest